Liraglutide modulates gut microbiota and reduces NAFLD in obese mice

Journal of Nutritional Biochemistry

Volumn 62, Issue , 2018, Pages 143-154

  Moreira, G V ^a   Azevedo, F F ^b   Ribeiro, L M ^a   Santos, A ^b   Guadagnini, D ^b   Gama, P ^a   Liberti, E A ^a   Saad, M J A ^b   Carvalho, C R O ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Analog of GLP 1; Gut microbiota; Liraglutide; NAFLD; Obesity

Indexed keywords

LIRAGLUTIDE;

AKKERMANSIA MUCINIPHILA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT LOSS; CECUM; CONTROLLED STUDY; FEMALE; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; INTESTINE FLORA; LIPID LIVER LEVEL; LIVER; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PROTEOBACTERIA; TREATMENT OUTCOME; ADIPOSE TISSUE; ADVERSE EVENT; ANIMAL; C57BL MOUSE; COMPLICATION; DRUG EFFECT; LIPID DIET; MICROBIOLOGY; MOUSE MUTANT; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADIPOSE TISSUE; ANIMALS; CECUM; DIET, HIGH-FAT; GASTROINTESTINAL MICROBIOME; LIRAGLUTIDE; MALE; MICE, INBRED C57BL; MICE, OBESE; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY;

EID: 85054354989     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2018.07.009     Document Type: Article

References (51)

1. Tilg, H., Cani, P.D., Mayer, E.A., Gut microbiome and liver diseases. Gut 65 (2016), 2035–2044, 10.1136/gutjnl-2016-312729.
2. Bäckhed, F., Ley, R.E., Sonnenburg, J.L., Peterson, D.A., Gordon, J.I., Host–bacterial mutualism in the human intestine. Science 307 (2005), 1915–1920, 10.1126/science.1104816.
3. Shanahan, F., The host-microbe interface within the gut. Baillieres Best Pract Res Clin Gastroenterol 16 (2002), 915–931, 10.1053/bega.2002.0342.
4. Kirpich, I.A., Marsano, L.S., McClain, C.J., Gut–liver axis, nutrition, and non-alcoholic fatty liver disease. Clin Biochem 48 (2015), 923–930, 10.1016/j.clinbiochem.2015.06.023.
5. Le Roy, T., Llopis, M., Lepage, P., Bruneau, A., Rabot, S., Bevilacqua, C., et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 62 (2013), 1787–1794, 10.1136/gutjnl-2012-303816.
6. Everard, A., Lazarevic, V., Gaïa, N., Johansson, M., Ståhlman, M., Backhed, F., et al. Microbiome of prebiotic-treated mice reveals novel targets involved in host response during obesity. ISME J 8 (2014), 2116–2130, 10.1038/ismej.2014.45.
7. Montandon, S.A., Jornayvaz, F.R., Effects of antidiabetic drugs on gut microbiota composition. Genes (Basel), 8, 2017, 250, 10.3390/genes8100250.
8. Knudsen, L.B., Nielsen, P.F., Huusfeldt, P.O., Johansen, N.L., Madsen, K., Pedersen, F.Z., et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 43 (2000), 1664–1669, 10.1021/jm9909645.
9. Rask, E., Olsson, T., Söderberg, S., Johnson, O., Seckl, J., Holst, J.J., et al. Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care 24 (2001), 1640–1645, 10.2337/diacare.24.9.1640.
10. Cani, P.D., Everard, A., Duparc, T., Gut microbiota, enteroendocrine functions and metabolism. Curr Opin Pharmacol 13 (2013), 935–940, 10.1016/j.coph.2013.09.008.
11. Hwang, I., Park, Y.J., Kim, Y.-R., Kim, Y.N., Ka, S., Lee, H.Y., et al. Alteration of gut microbiota by vancomycin and bacitracin improves insulin resistance via glucagon-like peptide 1 in diet-induced obesity. FASEB J 29 (2015), 2397–2411, 10.1096/fj.14-265983.
12. Everard, A., Cani, P.D., Gut microbiota and GLP-1. Rev Endocr Metab Disord, 2014, 189–196, 10.1007/s11154-014-9288-6.
13. Tsuda, T., Possible abilities of dietary factors to prevent and treat diabetes via the stimulation of glucagon-like peptide-1 secretion. Mol Nutr Food Res 59 (2015), 1264–1273, 10.1002/mnfr.201400871.
14. Dalgaard, M., Thomsen, C., Rasmussen, B.M., Holst, J.J., Hermansen, K., Ethanol with a mixed meal decreases the incretin levels early postprandially and increases postprandial lipemia in type 2 diabetic patients. Metabolism 53 (2004), 77–83, 10.1016/j.metabol.2003.08.011.
15. Iwasaki, M., Hoshian, F., Tsuji, T., Hirose, N., Matsumoto, T., Kitatani, N., et al. Predicting efficacy of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels. J Diabetes Investig 3 (2012), 464–467, 10.1111/j.2040-1124.2012.00214.x.
16. Sturis, J., Gotfredsen, C.F., Rømer, J., Rolin, B., Ribel, U., Brand, C.L., et al. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 140 (2003), 123–132, 10.1038/sj.bjp.0705397.
17. Bonora, E., Targher, G., Alberiche, M., Bonadonna, R.C., Saggiani, F., Zenere, M.B., et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 23 (2000), 57–63, 10.2337/diacare.23.1.57.
18. Scott, A.M., Atwater, I., Rojas, E., A method for the simultaneous measurement of insulin release and B cell membrane potential in single mouse islets of Langerhans. Diabetologia 21 (1981), 470–475.
19. Marçal, A.C., Camporez, J.P.G., Lima-Salgado, T.M., Cintra, D.E., Akamine, E.H., Ribeiro, L.M., et al. Changes in food intake, metabolic parameters and insulin resistance are induced by an isoenergetic, medium-chain fatty acid diet and are associated with modifications in insulin signalling in isolated rat pancreatic islets. Br J Nutr 109 (2013), 2154–2165, 10.1017/S0007114512004576.
20. Cani, P.D., Delzenne, N.M., Gut microflora as a target for energy and metabolic homeostasis. Curr Opin Clin Nutr Metab Care 10 (2007), 729–734, 10.1097/MCO.0b013e3282efdebb.
21. Robertson, C.E., Harris, J.K., Wagner, B.D., Granger, D., Browne, K., Tatem, B., et al. Explicet: graphical user interface software for metadata-driven management, analysis and visualization of microbiome data. Bioinformatics 29 (2013), 3100–3101, 10.1093/bioinformatics/btt526.
22. Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W.S., et al. Metagenomic biomarker discovery and explanation. Genome Biol, 12, 2011, R60, 10.1186/gb-2011-12-6-r60.
23. Kleiner, D.E., Brunt, E.M., Van Natta, M., Behling, C., Contos, M.J., Cummings, O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005), 1313–1321, 10.1002/hep.20701.
24. Deacon, C.F., Is endogenous GLP-1 the only important enhancer of glucose-induced insulin secretion in type 2 diabetes?. Diabetes 61 (2012), 2219–2220, 10.2337/db12-0649.
25. Turnbaugh, P.J., Ley, R.E., Mahowald, M.A., Magrini, V., Mardis, E.R., Gordon, J.I., An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444 (2006), 1027–1031, 10.1038/nature05414.
26. Ley, R.E., Bäckhed, F., Turnbaugh, P., Lozupone, C.A., Knight, R.D., Gordon, J.I., Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 102 (2005), 11070–11075, 10.1073/pnas.0504978102.
27. Remely, M., Hippe, B., Zanner, J., Aumueller, E., Brath, H.G., Haslberger, A., Gut microbiota of obese, type 2 diabetic individuals is enriched in Faecalibacterium prausnitzii, Akkermansia muciniphila and Peptostreptococcus anaerobius after weight loss. Endocr Metab Immune Disord Drug Targets 16 (2016), 99–106, 10.2174/1871530316666160831093813.
28. Duncan, S.H., Lobley, G.E., Holtrop, G., Ince, J., Johnstone, A.M., Louis, P., et al. Human colonic microbiota associated with diet, obesity and weight loss. Int J Obes (Lond) 32 (2008), 1720–1724, 10.1038/ijo.2008.155.
29. Hu, H.-J., Park, S.-G., Jang, H.B., Choi, M.-G., Park, K.-H., Kang, J.H., et al. Obesity alters the microbial community profile in Korean adolescents. PLoS One, 10, 2015, e0134333, 10.1371/journal.pone.0134333.
30. Dalby, M.J., Ross, A.W., Walker, A.W., Morgan, P.J., Dietary uncoupling of gut microbiota and energy harvesting from obesity and glucose tolerance in mice. Cell Rep 21 (2017), 1521–1533, 10.1016/j.celrep.2017.10.056.
31. Wang, L., Li, P., Tang, Z., Yan, X., Feng, B., Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment. Sci Rep, 6, 2016, 33251, 10.1038/srep33251.
32. Zhang, Q., Xiao, X., Zheng, J., Li, M., Yu, M., Ping, F., et al. Featured article: structure moderation of gut microbiota in liraglutide-treated diabetic male rats. Exp Biol Med 243 (2018), 34–44, 10.1177/1535370217743765.
33. Vilsbøll, T., Garber, A.J., Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide. Diabetes Obes Metab 14 (2012), 41–49, 10.1111/j.1463-1326.2012.01579.x.
34. Ladenheim, E., Liraglutide and obesity: a review of the data so far. Drug Des Devel Ther, 9, 2015, 1867, 10.2147/DDDT.S58459.
35. Bugáňová M., Pelantová H., Holubová M., Šedivá B., Maletínská L., Železná B., et al. The effects of liraglutide in mice with diet-induced obesity studied by metabolomics. J Endocrinol 233 (2017), 93–104, 10.1530/JOE-16-0478.
36. Derrien, M., van Passel, M.W., van de Bovenkamp, J.H., Schipper, R.G., de Vos, W.M., Dekker, J., Mucin-bacterial interactions in the human oral cavity and digestive tract. Gut Microbes 1 (2010), 254–268, 10.4161/gmic.1.4.12778.
37. Tailford, L.E., Crost, E.H., Kavanaugh, D., Juge, N., Mucin glycan foraging in the human gut microbiome. Front Genet, 6, 2015, 10.3389/fgene.2015.00081.
38. Johansson, M.E.V., Larsson, J.M.H., Hansson, G.C., The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. Proc Natl Acad Sci U S A 108 (2011), 4659–4665, 10.1073/pnas.1006451107 [Suppl].
39. Merga, Y., Campbell, B.J., Rhodes, J.M., Mucosal barrier, bacteria and inflammatory bowel disease: possibilities for therapy. Dig Dis 32 (2014), 475–483, 10.1159/000358156.
40. Betrapally, N.S., Gillevet, P.M., Bajaj, J.S., Changes in the intestinal microbiome and alcoholic and nonalcoholic liver diseases: causes or effects?. Gastroenterology 150 (2016), 1745–1755.e3, 10.1053/j.gastro.2016.02.073.
41. Le Chatelier, E., Nielsen, T., Qin, J., Prifti, E., Hildebrand, F., Falony, G., et al. Richness of human gut microbiome correlates with metabolic markers. Nature 500 (2013), 541–546, 10.1038/nature12506.
42. Zhu, L., Baker, S.S., Gill, C., Liu, W., Alkhouri, R., Baker, R.D., et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 57 (2013), 601–609, 10.1002/hep.26093.
43. Mutlu, E.A., Gillevet, P.M., Rangwala, H., Sikaroodi, M., Naqvi, A., Engen, P.A., et al. Colonic microbiome is altered in alcoholism. Am J Physiol Gastrointest Liver Physiol 302 (2012), G966–G978, 10.1152/ajpgi.00380.2011.
44. Yadav, H., Lee, J.H., Lloyd, J., Walter, P., Rane, S.G., Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J Biol Chem 288 (2013), 25088–25097, 10.1074/jbc.M113.452516.
45. Chichlowski, M., Sharp, J.M., Vanderford, D.A., Myles, M.H., Hale, L.P., Helicobacter typhlonius and Helicobacter rodentium differentially affect the severity of colon inflammation and inflammation-associated neoplasia in IL10-deficient mice. Comp Med 58 (2008), 534–541.
46. Beaumont, M., Goodrich, J.K., Jackson, M.A., Yet, I., Davenport, E.R., Vieira-Silva, S., et al. Heritable components of the human fecal microbiome are associated with visceral fat. Genome Biol, 17, 2016, 189, 10.1186/s13059-016-1052-7.
47. Del Chierico, F., Nobili, V., Vernocchi, P., Russo, A., De Stefanis, C., Gnani, D., et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. Hepatology 65 (2017), 451–464, 10.1002/hep.28572.
48. Loomba, R., Seguritan, V., Li, W., Long, T., Klitgord, N., Bhatt, A., et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab 25 (2017), 1054–1062.e5, 10.1016/j.cmet.2017.04.001.
49. Rotman, Y., Sanyal, A.J., Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut 66 (2017), 180–190, 10.1136/gutjnl-2016-312431.
50. Everard, A., Belzer, C., Geurts, L., Ouwerkerk, J.P., Druart, C., Bindels, L.B., et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. 2013, 10.1073/pnas.1219451110.
51. Smits, M.M., Tonneijck, L., Muskiet, M.H.A., Hoekstra, T., Kramer, M.H.H., Diamant, M., et al. Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients. Diabetes Obes Metab 18 (2016), 1217–1225, 10.1111/dom.12748.